Shionogi gibt die Zulassung von XOFLUZA® (Baloxavir marboxil) durch die Europäische Kommission zur Behandlung und Postexpositionsprophylaxe von Influenzavirus-Infektionen bekannt
To improve your experience, this website uses cookies for analytics and functionality purposes. More information about how we use cookies and how you can control them is in our Cookie Policy. By continuing to use our website you agree to our use of these cookies.
